Long-term safety and efficacy of daclizumab beta in relapsing –remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
ConclusionsThe effects of daclizumab beta on clinical and radiologic outcomes were sustained for up to ~ 8 years of treatment. No new safety concerns were identified in SELECTED.Trial registrationClinicaltrials.gov NCT01051349; first registered on January 15, 2010.
Source: Journal of Neurology - Category: Neurology Source Type: research